|
注册号: Registration number: |
ChiCTR2500097619 |
|
最近更新日期: Date of Last Refreshed on: |
2025-02-21 17:05:38 |
|
注册时间: Date of Registration: |
2025-02-21 00:00:00 |
|
注册号状态: |
补注册 |
|
Registration Status: |
Retrospective registration |
|
注册题目: |
神经肌肉学结合生物力学的肩胛稳定肌矫正训练对中国中学生上交叉综合征的影响研究 |
|
Public title: |
The Effect of Neuromuscular Combined with Biomechanical Scapular Stabilizer Correction Training on Upper Cross Syndrome in Secondary School Students |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
神经肌肉学结合生物力学的肩胛稳定肌矫正训练对中学生上交叉综合征的影响研究 |
|
Scientific title: |
The Effect of Neuromuscular Combined with Biomechanical Scapular Stabilizer Correction Training on Upper Cross Syndrome in Secondary School Students |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
胡轩鸣 |
研究负责人: |
胡轩鸣 |
|
Applicant: |
Xuanming Hu |
Study leader: |
Xuanming Hu |
|
申请注册联系人电话: Applicant telephone: |
+86 158 4757 1458 |
研究负责人电话:
Study leader's |
+86 158 4757 1458 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
840576935@qq.com |
研究负责人电子邮件: Study leader's E-mail: |
840576935@qq.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
南京市玄武区灵谷寺路8号 |
研究负责人通讯地址: |
南京市玄武区灵谷寺路8号 |
|
Applicant address: |
No. 8 Linggusi Road, Xuanwu District, Nanjing |
Study leader's address: |
No. 8 Linggusi Road, Xuanwu District, Nanjing |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
南京体育学院 |
||
|
Applicant's institution: |
Nanjing Sport Institute |
||
|
研究负责人所在单位: |
南京体育学院 |
||
|
Affiliation of the Leader: |
Nanjing Sport Institute |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
RT-2024-13 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
南京体育学院人体实验伦理委员会 |
||
|
Name of the ethic committee: |
Human Experiment Ethics Committee of Nanjing University of Physical Education |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2024-07-10 00:00:00 | ||
|
伦理委员会联系人: |
陈磊 |
||
|
Contact Name of the ethic committee: |
Lei Chen |
||
|
伦理委员会联系地址: |
南京市玄武区灵谷寺路8号 |
||
|
Contact Address of the ethic committee: |
No. 8 Linggusi Road, Xuanwu District, Nanjing |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 25 8475 0882 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
南京体育学院 |
||||||||||||||||||||||
|
Primary sponsor: |
Nanjing Sports Institute |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
南京市玄武区灵谷寺路8号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No. 8 Linggusi Road, Xuanwu District, Nanjing |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
自筹 |
||||||||||||||||||||||
|
Source(s) of funding: |
Self-funded |
||||||||||||||||||||||
|
研究疾病: |
上交叉综合征 |
||||||||||||||||||||||
|
Target disease: |
Upper cross syndrome |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
主要目的是评估神经肌肉结合生物力学锻炼对中学生上交叉综合征的影响。次要目的是比较神经肌肉结合生物力学锻炼与单独的生物力学锻炼的效果,并分析治疗效果的潜在机制。 |
||||||||||||||||||||||
|
Objectives of Study: |
The primary objective was to evaluate the effects of neuromuscular combined with biomechanical exercise (NCBE) on Upper cross syndrome in secondary school students. The secondary objective was to compare NCBE with biomechanical exercise (BE) alone and to analyze the potential mechanisms underlying the treatment effects. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
|||||||||||||||||||||||
|
Inclusion criteria |
|||||||||||||||||||||||
|
排除标准: |
存在疾病、骨折、手术史、关节问题、脊柱损伤、异常BMI、任何诊断出的肌肉病理状况,或颈椎软组织骨折,以及无法每周至少参加三次本试验锻炼的情况。 |
||||||||||||||||||||||
|
Exclusion criteria: |
Participants with a history of disease, fractures, surgeries, joint issues, spinal injuries, abnormal BMI, diagnosed muscular pathology, cervical soft tissue fractures, or those unable to attend at least three exercise sessions per week. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2024-07-10 00:00:00至 To 2024-10-13 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2024-07-15 00:00:00 至 To 2024-07-15 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
结束 /Completed |
年龄范围: Participant age: |
|
||||||
|
性别: |
男性 |
Gender: |
Male |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
在随机化之前,所有潜在参与者都接受了资格评估。使用计算机生成的随机化列表,采用区组随机化方法以确保参与者按1:1:1的比例分配到神经肌肉结合生物力学组(NCBE group)、生物力学组(BE group)和对照组(control group)。区组大小保密,以防预测分配。一名独立统计学家负责随机化过程,并与试验其他人员隔离,以确保他们不知道具体的组别分配。统计学家记录每个参与者的组别分配,并将其存储在数据库中,检查每个分层组合的随机化结果。 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
Prior to randomization, all potential participants underwent eligibility assessments. A computer-generated randomization list was used, employing block randomization to ensure participants were allocated in a 1:1:1 ratio to the neuromuscular combined with the biomechanical exercise group (NCBE group), the biomechanical exercise group (BE group), and the control group. The block size was kept confidential to prevent the prediction of group allocation. An independent statistician was responsible for the randomization process and was kept blinded by the trial personnel to ensure that group assignments were concealed. Statisticians recorded the group assignments for each participant, stored them in a secure database, and verified the randomization results for each stratification combination. |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
对参与者、执行干预的研究人员和数据分析人员进行盲法,提供的材料应尽量保持外观和操作流程的一致性,以避免无意间泄露分组信息。引入不直接参与试验操作的第三方帮助准备和管理干预材料,有助于维持盲态。为所有参与者分配唯一的代码,在数据分析阶段之前不对任何人公开实际的分组信息。只有当所有的数据收集和初步分析完成后,才解码并确定各组的实际身份。在整个过程中,详细记录任何可能导致盲态破坏的情况,并定期检查是否保持了应有的盲态。 |
|
Blinding: |
Participants, researchers performing interventions, and data analysts are blinded, and the materials provided should be as consistent in appearance and operation as possible to avoid inadvertent disclosure of group information. Introducing a third party who is not directly involved in the trial operation to help prepare and manage the intervention materials can help maintain blinding. All participants are assigned unique codes, and the actual group information is not disclosed to anyone until the data analysis phase. Only when all data collection and preliminary analysis are completed is the actual identity of the groups decoded and determined. Throughout the process, any circumstances that may lead to a breach of blinding are recorded in detail, and regular checks are made to ensure that proper blinding is maintained. |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
是Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
论文发表后6个月内上传至中国临床试验公共管理平台 ResMan网址:http://www.medresman.org.cn。 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
Within 6 months after publication, the paper will be uploaded to the website of ResMan, a public management platform for clinical trials in China, at http://www.medresman.org.cn. |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
电子采集和管理系统 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Electronic Data Capture |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |